Sitagliptin
- Generic Name
- Sitagliptin
- Brand Names
- Janumet, Januvia, Ristaben, Steglujan, Tesavel, Velmetia, Xelevia, Sitagliptin SUN, Sitagliptin Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H15F6N5O
- CAS Number
- 486460-32-6
- Unique Ingredient Identifier
- QFP0P1DV7Z
- Background
Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar. Sitagliptin was granted FDA approval on October 16, 2006.
- Indication
Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not used to treat type 1 diabetes or patients with a history of pancreatitis.
It is also used in combination with metformin or ertugliflozin.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant
- Conditions
- Interventions
- First Posted Date
- 2012-11-02
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- Sherif S. Farag
- Target Recruit Count
- 15
- Registration Number
- NCT01720264
- Locations
- 🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸New York Medical College/Westchester Medical Center/Maria Fareri Children's Hosptial, Valhalla, New York, United States
A Pilot Study to Assess the Glucose Lowering Effect of Metformin and Sitagliptin in Adolescents With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2012-10-31
- Last Posted Date
- 2017-04-24
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 21
- Registration Number
- NCT01718093
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
ß-Cell Function and Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients With Moderate Hyperglycemia
- First Posted Date
- 2012-10-31
- Last Posted Date
- 2012-10-31
- Lead Sponsor
- Taipei Veterans General Hospital, Taiwan
- Target Recruit Count
- 160
- Registration Number
- NCT01717911
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan
A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)
- Conditions
- Interventions
- First Posted Date
- 2012-10-18
- Last Posted Date
- 2018-08-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 5570
- Registration Number
- NCT01709305
Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020)
- Conditions
- Interventions
- First Posted Date
- 2012-10-10
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 414
- Registration Number
- NCT01703221
Efficacy and Safety Comparative Study of Sitagliptin,Vildagliptin and Saxagliptin
- Conditions
- Interventions
- First Posted Date
- 2012-10-10
- Last Posted Date
- 2016-03-31
- Lead Sponsor
- Lin Liao
- Target Recruit Count
- 300
- Registration Number
- NCT01703637
- Locations
- 🇨🇳
YuCheng people's hospital, Dezhou, Shandong, China
🇨🇳Hospital of SINOTRUK, Jinan, Shandong, China
🇨🇳Jinan central hospital, Jinan, Shandong, China
Effect of DPP4 Inhibition on Growth Hormone Secretion
- Conditions
- Interventions
- First Posted Date
- 2012-10-05
- Last Posted Date
- 2018-05-29
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 44
- Registration Number
- NCT01701973
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Vildagliptin vs Sitagliptin add-on to Insulin - Impact on Glycemic Profile and Correlation of Hypoglycemic Episodes and Heart Function
- First Posted Date
- 2012-09-18
- Last Posted Date
- 2016-03-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 51
- Registration Number
- NCT01686932
- Locations
- 🇩🇪
Novartis Investigative Site, Wallerfing, Germany
A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)
- First Posted Date
- 2012-09-05
- Last Posted Date
- 2018-08-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 299
- Registration Number
- NCT01678820
Study of Comparing the Different Effect of DPP-4 Inhibitors and Sulfonylurea by Using "Biphase-Hyperglycemic Clamp"
- Conditions
- Interventions
- First Posted Date
- 2012-08-08
- Last Posted Date
- 2012-12-17
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 12
- Registration Number
- NCT01660386
- Locations
- 🇨🇳
Shanghai Jiao Tong University School of Medicine, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.